Comparison of intravenous thrombolysis agents for acute ischemic stroke: a systematic review and network meta-analysis
Abstract
BackgroundIntravenous thrombolysis (IVT) is the most important treatment for acute ischemic stroke (AIS) patients within 4.5 h of symptom onset, but the lack of head-to-head trials prevents comparisons of the IVT agents’ efficacy and safety, posing challenges for the selection of the best IVT agent. We aimed to evaluate all IVT agents’ effectiveness and safety in AIS treatment within 4.5 h of symptom onset.MethodsWe conducted a frequentist random-effects network meta-analysis to calculate relative risks (RRs) along with 95% confidence intervals (95% CI) using Stata. Between-study clinical and methodological heterogeneity was evaluated through pre-specified subgroup and sensitivity analyses; because the evidence formed a star-shaped network centered on alteplase (rt-PA) without closed loops, a consistency model was fitted. The primary efficacy outcome was excellent functional outcome (modified Rankin Scale [mRS] 0–1 at 90 days), and the primary safety outcome was symptomatic intracranial hemorrhage (SICH, ECASS III criteria) within 24–48 h. Secondary functional and safety outcomes were also evaluated. The risk of bias and the quality of evidence were assessed with the Cochrane Risk of Bias tool and the Confidence in Network Meta-Analysis tool.ResultsNineteen RCTs involving 14,464 patients evaluated five IVT agents (rt-PA, tenecteplase [TNK], reteplase [rPA], recombinant human prourokinase [rhPro-UK], and staphylokinase [SAK]) and placebo. For primary efficacy outcome (mRS 0–1 at 90 days): SUCRA ranking was SAK (91.3%), rPA (83.8%), rhPro-UK (51.2%), TNK (50.5%), and rt-PA (23.2%). Compared with rt-PA, rPA significantly increased the likelihood of excellent recovery (RR 1.13, 95% CI: 1.06–1.19; high certainty), outperforming TNK (RR 1.09, 95% CI: 1.01–1.16; high certainty) and rhPro-UK (RR 1.08, 95% CI: 1.00–1.17; high certainty). TNK was also associated with a higher likelihood of excellent recovery compared with rt-PA (RR 1.04, 95% CI: 1.00–1.08; moderate certainty). For primary safety outcome (24–48 h SICH): SUCRA ranking for reducing bleeding risk was rhPro-UK (97.4%), rt-PA (56.5%), rPA (29.3%), and TNK (16.9%). rhPro-UK conferred a significantly lower risk of SICH compared with TNK (RR 0.23, 95% CI: 0.06–0.87; moderate certainty). No significant differences in SICH risk were detected among rPA, TNK, and rt-PA. No significant differences were observed across agents for 90-day all-cause mortality or any intracranial hemorrhage.ConclusionThe rPA and TNK were associated with improved functional recovery compared with standard rt-PA, while rhPro-UK demonstrated potential in minimizing sICH risk, and direct head-to-head randomized trials remain needed.Systematic review registrationPROSPERO, CRD42024615928.
Related
- Early antiplatelet therapy after intravenous thrombolysis in acute non-cardiogenic ischemic stroke: a systematic review and meta-analysis
- Extending the Treatment Window for Intravenous Thrombolysis in Acute Ischemic Stroke
- Success rate and determinants of intravenous thrombolysis in acute ischemic stroke from the Malaysia National Stroke Registry
- Machine learning-based models to predict 90-day non-excellent functional outcomes among patients with mild acute ischemic stroke after intravenous thrombolysis
- Intravenous thrombolysis in acute ischemic stroke after reversal of warfarin anticoagulation in patients with mechanical heart valve prostheses and an INR > 1.7
BibTeX
@article{xu2026comparison,
title = {{Comparison of intravenous thrombolysis agents for acute ischemic stroke: a systematic review and network meta-analysis}},
author = {Rufan Xu and Na Li and Sisong Cheng and Xinxing Lai and Hongrui Zhang and Yonghong Gao and Mingzhen Qin and Zhenhong Liu and Luda Feng and Ying Gao},
journal = {Frontiers in Pharmacology},
year = {2026},
month = nov,
doi = {10.3389/fphar.2026.1884696},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1884696},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Comparison of intravenous thrombolysis agents for acute ischemic stroke: a systematic review and network meta-analysis
AU - Rufan Xu
AU - Na Li
AU - Sisong Cheng
AU - Xinxing Lai
AU - Hongrui Zhang
AU - Yonghong Gao
AU - Mingzhen Qin
AU - Zhenhong Liu
AU - Luda Feng
AU - Ying Gao
PY - 2026
DA - 2026/11/05
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1884696
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1884696
AB - BackgroundIntravenous thrombolysis (IVT) is the most important treatment for acute ischemic stroke (AIS) patients within 4.5 h of symptom onset, but the lack of head-to-head trials prevents comparisons of the IVT agents’ efficacy and safety, posing challenges for the selection of the best IVT agent. We aimed to evaluate all IVT agents’ effectiveness and safety in AIS treatment within 4.5 h of symptom onset.MethodsWe conducted a frequentist random-effects network meta-analysis to calculate relative risks (RRs) along with 95% confidence intervals (95% CI) using Stata. Between-study clinical and methodological heterogeneity was evaluated through pre-specified subgroup and sensitivity analyses; because the evidence formed a star-shaped network centered on alteplase (rt-PA) without closed loops, a consistency model was fitted. The primary efficacy outcome was excellent functional outcome (modified Rankin Scale [mRS] 0–1 at 90 days), and the primary safety outcome was symptomatic intracranial hemorrhage (SICH, ECASS III criteria) within 24–48 h. Secondary functional and safety outcomes were also evaluated. The risk of bias and the quality of evidence were assessed with the Cochrane Risk of Bias tool and the Confidence in Network Meta-Analysis tool.ResultsNineteen RCTs involving 14,464 patients evaluated five IVT agents (rt-PA, tenecteplase [TNK], reteplase [rPA], recombinant human prourokinase [rhPro-UK], and staphylokinase [SAK]) and placebo. For primary efficacy outcome (mRS 0–1 at 90 days): SUCRA ranking was SAK (91.3%), rPA (83.8%), rhPro-UK (51.2%), TNK (50.5%), and rt-PA (23.2%). Compared with rt-PA, rPA significantly increased the likelihood of excellent recovery (RR 1.13, 95% CI: 1.06–1.19; high certainty), outperforming TNK (RR 1.09, 95% CI: 1.01–1.16; high certainty) and rhPro-UK (RR 1.08, 95% CI: 1.00–1.17; high certainty). TNK was also associated with a higher likelihood of excellent recovery compared with rt-PA (RR 1.04, 95% CI: 1.00–1.08; moderate certainty). For primary safety outcome (24–48 h SICH): SUCRA ranking for reducing bleeding risk was rhPro-UK (97.4%), rt-PA (56.5%), rPA (29.3%), and TNK (16.9%). rhPro-UK conferred a significantly lower risk of SICH compared with TNK (RR 0.23, 95% CI: 0.06–0.87; moderate certainty). No significant differences in SICH risk were detected among rPA, TNK, and rt-PA. No significant differences were observed across agents for 90-day all-cause mortality or any intracranial hemorrhage.ConclusionThe rPA and TNK were associated with improved functional recovery compared with standard rt-PA, while rhPro-UK demonstrated potential in minimizing sICH risk, and direct head-to-head randomized trials remain needed.Systematic review registrationPROSPERO, CRD42024615928.
SN - 1663-9812
ER -